References
- Hepatitis C. 2015 [cited 2015 Aug 27]; Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
- CDC. HIV and Viral Hepatitis. March 2014 [cited 2015 Nov 5; Available from: http://www.cdc.gov/hepatitis/populations/pdfs/hivandhep-factsheet.pdf.
- WHO. HIV and hepatitis coinfections. [cited 2015 Nov 20]; Available from: http://www.who.int/hiv/topics/hepatitis/hepatitisinfo/en/
- Graham CS, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–569.
- Terrault NA, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18(6):716–726.
- Afdhal N, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.
- Afdhal N, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.
- Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015;9(2):161–173.
- Harvoni [package insert]. Foster City, CA. Gilead Sciences; 2014. [cited 2015 10 1]; Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
- Harvoni. In: Micromedex. Ann Arbor (MI): Truven Health Analytics. [cited 2015 Nov 15]
- Fontaine H, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373(19):1886–1888.
- Renet S, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149(6):1378–1380 e1.
- Terrault NA, Zeuzem S, Di Bisceglie AM, et al. (HCV-TARGET) - treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. AASLD 2015; 2015 Nov 13–17; San Francisco, CA.
- Lontok E, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62(5):1623–1632.
- Kowdley KV, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.
- Kattakuzhy S, et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis. 2016;62(4):440–7.
- Wilson EM, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis. 2016;62(3):280–8.
- Lawitz E. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. EASL - The International Liver Congress 2015; 2015 Apr 22–26; Vienna.
- Osinusi A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Jama. 2015;313(12):1232–9.
- Naggie S, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705–13.
- El-Sherif O, Khoo S, Solas C. Key drug–drug interactions with direct-acting antiviral in HIV-HCV coinfection. Curr Opin HIV AIDS. 2015;10(5):348–354.
- German P. Pharmacokinetic analyses of ledipasvir/sofosbuvir and HIV antiretroviral regimens in subjects with HCV/HIV coinfection. AASLD 2015; 2015 Nov 13–17; San Francisco, CA.
- AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2015 [cited 2015 Nov 5]. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/26/hiv-hcv.
- Ingiliz P, Sofosbuvir plus ledipasvir for 8 weeks in HCV-mono- and HIV-HCV-coinfected patients - results from the German Hepatitis C Cohort (GECCO). in 15th European AIDS Conference. Barcelona, October 21–24, 2015.
- Osinusi A, Townsend K, Kottilil S. Drug–drug interactions in patients co-infected with HCV and HIV–reply. Jama. 2015;314(2):186–187.
- Genvoya [package insert]. Foster City, CA: Gilead Sciences; 2015.
- Sulkowski MS, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama. 2015;313(12):1223–31.
- Wyles DL, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–25.
- Rockstroh JK, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27.
- Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin Infect Dis. 2015;61(12):1825–1830.
- Barua S, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215–223.
- Lo Re V. Incidence and determinants of denial of DAA treatment for chronic HCV infection by insurance type during the first 6 months of the modern HCV treatment era. AASLD 2015; 2015 Nov 13–17; San Francisco, CA.
- Silverman E. 2015 Feb 4. What the ‘shocking’ Gilead discounts on its hepatitis C drugs will mean. The Wall Street Journal [Internet]. [cited 2015 Oct 19]. Available from: http://blogs.wsj.com/pharmalot/2015/02/04/what-the-shocking-gilead-discounts-on-its-hepatitis-c-drugs-will-mean/
- Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015;119:89–96.